AbbVie Completes Apogee Therapeutics Acquisition, Declares Quarterly Dividend and Unveils Positive Menstrual Migraine Trial Data

AbbVie Inc. (NYSE: ABBV) finalized its acquisition of Apogee Therapeutics on September 3, solidifying a $10.9 billion addition to its immunology pipeline, and on September 10 the company declared a quarterly dividend of $1.73 per share, while also unveiling positive Phase 3 topline results for its atogepant treatment in menstrual migraine—milestones that mark a significant week for shareholders and growth strategy.

Acquisition Completion: Apogee Therapeutics

On September 3, 2026, AbbVie confirmed the completion of its acquisition of Apogee Therapeutics, advancing its expansion in the immunology space through Apogee’s late-stage clinical assets. The agreed deal, valued at approximately $10.9 billion, includes development candidates targeting atopic dermatitis and asthma such as zumilokibart (APG777) and APG273.

This acquisition was first announced in June 2026 and had been expected to close in the third quarter; its completion marks a key milestone in AbbVie’s long-term strategic growth in inflammatory and immunological diseases.

Dividend Declaration

On September 10, 2026, AbbVie’s board declared a quarterly cash dividend of $1.73 per share, payable November 16, 2026, to shareholders of record as of the dividend record date. This move reflects continued shareholder returns alongside product and pipeline expansion.

Positive Phase 3 Results in Menstrual Migraine

Also on September 10, AbbVie reported encouraging topline results from a Phase 3 clinical trial studying atogepant, an existing migraine therapy, in menstrual migraine. The trial reportedly met its primary and key secondary endpoints, reinforcing AbbVie’s leadership in migraine treatments and supporting potential label expansion into menstrual migraine.

Stock Performance Snapshot

AbbVie’s stock has shown resilience amid these developments. On September 10, 2026, the share price closed at approximately $255.00, up about 1.63% from the prior day—reflecting positive market reception to the medical and financial announcements. The prior trading session (September 9) saw AbbVie trading around $250.90.

Separately, analysts noted a surge of around 6.2% in the prior week, placing ABBV within ~0.9% of its 52-week high—though that momentum preceded the September announcements.

Significance for Investors

The acquisition of Apogee expands AbbVie’s pipeline with potentially blockbuster immunology assets, offering a clear vertical integration opportunity. Meanwhile, the dividend declaration reinforces reliable cash returns for investors. Positive Phase 3 data for menstrual migraine positions AbbVie to extend the label of atogepant into a predictable and underserved segment, which could enhance future sales.

Together, these developments provide both strategic depth and near-term investor value, strengthening AbbVie’s profile in the S&P 500 pharmaceutical space.

What’s Next

Investors should watch for integration updates on the Apogee acquisition and full clinical data for the menstrual migraine trial that could inform label expansion. The dividend is scheduled for distribution on November 16, 2026. Market reaction in coming sessions and any analyst commentary will further clarify the share price trajectory.

Live verified stock price: ABBV closed at roughly $257.12, a 1.26% gain as of September 11, 2026.